AI Bowel Cancer Test Determines Need for Chemotherapy in Patients: Study
A study published in the Journal of Clinical Oncology reveals that a new artificial intelligence (AI) test can assess the risk of bowel cancer recurrence and potentially help patients avoid chemotherapy. Led by researchers at the University of Leeds, the test uses an AI algorithm to accurately evaluate the presence of CD3 immune cells in early-stage bowel cancer tumours. Bowel cancer, also known as colorectal cancer, affects the large bowel, including the colon and rectum, and was diagnosed in 1.9 million cases globally in 2020.
In the study, the CD3 Score test reliably showed which stage II cancers were most likely to recur within five years of surgery – and this could be used by clinicians to decide which patients may need further treatment such as chemotherapy.
Current methods for deciding which patients with early-stage bowel cancer need chemotherapy and which do not are unreliable. Many people receive chemotherapy when they don’t need it, and unfortunately some of the people who are not offered chemotherapy go on to experience cancer recurrence.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.